What's Happening?
Incyte has announced promising results from its Phase 1/2 multidose study of VGA039 (latarcibart), a novel monoclonal antibody targeting Protein S, aimed at treating patients with von Willebrand disease (VWD). The study, presented at the International
Society on Thrombosis and Haemostasis (ISTH) 2026 Congress, demonstrated an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types. Latarcibart, administered once monthly via subcutaneous injection, was found to be safe and well-tolerated. The drug is currently in pivotal Phase 3 development, with the potential to become the first targeted prophylactic therapy for VWD, offering an alternative to frequent intravenous infusions of replacement factor concentrates.
Why It's Important?
The development of latarcibart is significant as it addresses a critical need for more effective and convenient prophylactic treatments for VWD, a common inherited bleeding disorder affecting approximately 135,000 people in the U.S. Current treatments require multiple weekly intravenous infusions, which can be burdensome for patients. Latarcibart's once-monthly dosing could significantly reduce treatment burden while providing consistent bleed protection. This advancement could improve the quality of life for VWD patients and potentially set a new standard in prophylactic care, offering a more manageable treatment option.
What's Next?
Incyte is continuing to enroll patients in the Phase 3 VIVID-6 trial to further evaluate latarcibart's efficacy and safety. If successful, this trial could lead to regulatory approval, making latarcibart the first once-monthly subcutaneous prophylactic therapy for VWD. The company is also exploring latarcibart's potential in treating other bleeding disorders, which could expand its application and impact. The ongoing research and development efforts underscore Incyte's commitment to addressing unmet needs in bleeding disorder treatments.
